First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy

NCT03798535 · clinicaltrials.gov ↗
COMPLETED
Status
1156
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

AstraZeneca